Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. - Wikidata - awgldk - TriplyDB

Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting.

Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting.

http://www.wikidata.org/entity/Q37419758

about

Nicotine receptor partial agonists for smoking cessation Combined pharmacotherapy and behavioural interventions for smoking cessation Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation Nicotine receptor partial agonists for smoking cessation Telephone counselling for smoking cessation Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation Nicotine receptor partial agonists for smoking cessation Varenicline as a Cause of Suicidal Outcomes Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey.Rationale and design of a randomized controlled trial of varenicline directly observed therapy delivered in methadone clinics Usage patterns of stop smoking medications in Australia, Canada, the United Kingdom, and the United States: findings from the 2006-2008 International Tobacco Control (ITC) Four Country Survey Early quit days among methadone-maintained smokers in a smoking cessation trial Utilization of services in a randomized trial testing phone- and web-based interventions for smoking cessation.Adherence to varenicline in the COMPASS smoking cessation intervention trial.Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genes.Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness.Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial Use of Varenicline in Smokeless Tobacco Cessation: A Systematic Review and Meta-Analysis.Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis.Effectiveness of varenicline as an aid to smoking cessation in primary care: an observational study.Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial.An Open Trial of Electronic Cigarettes for Smoking Cessation Among Methadone-Maintained Smokers.

P2860

Q24185773-841BB6EF-F1FA-4A15-8B04-B6AFF355D8DA Q24186008-F7DD7A88-B7BD-4666-A4A7-E86B1781C4B4 Q24186545-A1C46D58-52A7-498B-A103-8F562280FAD4 Q24200322-A00C9CFF-64B1-4447-9758-C9ACAFBDA354 Q24200452-C66E0E06-58EA-48F6-926F-1A45B57E0E76 Q24202466-D104129D-BB6E-45A8-81D8-24F3F2D4E4D2 Q24235456-4AA979E6-6C49-4A55-9E07-9072E87247F0 Q28255130-21D52C4A-3B5C-419C-AEF9-E192A7CBF08D Q33767740-DC102EB1-6A05-404C-9D43-3C36323EE483 Q33854297-ECA82C57-AAED-4852-B3C8-499B3B852E60 Q34566194-482B3FE0-580C-40D3-A374-5D430ECE8189 Q34736698-3F928FE3-A74E-49AB-8871-CBFB4FA59E65 Q34859437-59591DB9-6CA8-42D7-932B-0047B834A9C0 Q34859460-AA8261F7-A1BD-4779-92A7-B2F2E872B1D9 Q36118485-699FA2D7-ED68-4879-9A78-C247E459402D Q37145902-BB9FFAB0-FF0A-4147-8BC1-6F270D4A1EC4 Q37160367-3B6A0143-5100-43E4-A49A-239EAB950EAE Q37282141-3C37B3D1-85D8-49A2-A7B9-1E18EAD44B64 Q38342207-EAE8B1EB-2BFE-4DD9-A99B-D1BA56FB8465 Q40456297-E0CACC5F-3D6F-4280-B688-2ECE3D115586 Q45065349-CAEF65AD-33AD-4E82-93A2-5D58BD1C7EE4 Q47275723-8419F57C-88DB-43B3-91E1-6DD1A78A2FD2 Q53645639-9DCF2269-0672-4E5D-A152-A3E2BCE76028

P2860

Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting.

http://www.wikidata.org/entity/Q37419758

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Impact of symptoms experienced ...... tment in a real world setting.

@en

Impact of symptoms experienced ...... tment in a real world setting.

@nl

type

label

Impact of symptoms experienced ...... tment in a real world setting.

@en

Impact of symptoms experienced ...... tment in a real world setting.

@nl

prefLabel

Impact of symptoms experienced ...... tment in a real world setting.

@en

Impact of symptoms experienced ...... tment in a real world setting.

@nl

P1433

Q37419758-DF351ED9-8B24-45FA-AC4F-DCB4DB317373

P1476

Q37419758-4323347B-3CBB-4452-8D4D-A580668776C4

P2093

Q37419758-30FB3378-B471-4999-9A71-0D2EC1B095F2

Q37419758-3DD084DF-3488-464F-BDF0-A70A5DE0CD2C

Q37419758-751A7E9F-2D35-4189-A47B-B92F41E0138E

Q37419758-78610A6F-78DA-4E96-9C6B-684A58DFAB6C

Q37419758-7FAC1829-C1AA-43C3-A06E-6C05A2B4136E

Q37419758-A566B100-9EC9-4BBE-999F-C4F39AD80082

Q37419758-BE0E2A72-40B0-44C7-B82B-5CF56EE990FC

Q37419758-BFAAA01D-20A5-422F-A7D3-4608115F4BA8

P2860

Q37419758-01B31CF0-044C-436E-BD58-84173FCA523D

Q37419758-63580B1E-5DBB-44FC-9649-7238F6EFC88B

Q37419758-6C04EAD5-4435-4497-8A1E-9C67E2D40FB2

Q37419758-73C5114D-E36C-485F-86CF-AE5DBA5E90C5

Q37419758-76463970-EBA3-49D5-95D1-7BA8E1EF715C

Q37419758-8EAE8651-FEF4-4987-BE0E-3F08482EF710

Q37419758-CB095F55-9109-444F-92C8-2277C82C6D4F

Q37419758-D6B4FBFB-107C-49F0-906A-ED1AA3ADE2F6

P304

Q37419758-0E68C6A4-9514-4042-BA60-13F0B42379F3

P31

Q37419758-4BB0B698-C7D4-4CDE-AD82-5BACDC080633

P356

Q37419758-248B73CE-DD1C-4D25-9CE1-4DC3F2E42407

P433

Q37419758-2987C64B-88A4-41DA-B690-97BA15AC03F9

P478

Q37419758-F6D853B1-94D7-4D1A-963F-988168B0570C

P50

Q37419758-D109ABF8-66EA-4272-9F58-BF73A6AC4D6E

P577

Q37419758-6545B7DF-4656-40BE-9D8C-DF8F0DD1884B

P5875

Q37419758-38235F95-4A3E-4784-BA0D-67D8308E6D26

P698

Q37419758-712AAA58-69C1-4B4B-99C9-2013C10A9067

P932

Q37419758-D120CC3A-6A85-438B-8522-29EBABF3FD7F

P356

J.JSAT.2008.09.001

P1433

Journal of Substance Abuse Treatment

P1476

Impact of symptoms experienced ...... atment in a real world setting

@en

P2093

Abigail C Halperin

http://www.w3.org/2001/XMLSchema#string

Gary E Swan

http://www.w3.org/2001/XMLSchema#string

Jennifer B McClure

http://www.w3.org/2001/XMLSchema#string

Lisa M Jack

http://www.w3.org/2001/XMLSchema#string

Sheryl L Catz

http://www.w3.org/2001/XMLSchema#string

Susan M Zbikowski

http://www.w3.org/2001/XMLSchema#string

T Mona Deprey

http://www.w3.org/2001/XMLSchema#string

Timothy A McAfee

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Effects of abstinence from tobacco: valid symptoms and time course.

PharmGKB update: I. Genetic variants of the organic cation transporter 2 (OCT2, SLC22A2).

Factor structure and validity of the Medication Adherence Questionnaire (MAQ) with cigarette smokers trying to quit.

Treating tobacco dependence in women.

Gender differences in acute tobacco withdrawal: effects on subjective, cognitive, and physiological measures.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

P304

428-434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JSAT.2008.09.001

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Julie E Richards

P577

2008-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23469042

http://www.w3.org/2001/XMLSchema#string

P698

19004600

http://www.w3.org/2001/XMLSchema#string

P932

2776715

http://www.w3.org/2001/XMLSchema#string